Game-Changer: Every-2-Month HIV Jab for India

A major breakthrough in HIV prevention has emerged with the approval of the Cabotegravir Long-Acting (CAB-LA) jab in the UK. This innovative treatment, requiring administration only every two months, could be a game-changer in the fight against HIV, especially for those who find it challenging to take daily pills due to stigma, side effects, or busy lifestyles. The slow-release formula of the jab maintains protective drug levels in the blood, ensuring continued protection even if someone forgets a dose.

Currently, the UK has one of the highest rates of PrEP usage in Europe. However, health experts have struggled to reach individuals facing pill fatigue or social stigma. For many, taking an HIV prevention pill daily can be emotionally and socially burdensome. The introduction of CAB-LA could significantly reduce new HIV cases among key populations who have difficulties accessing daily medication.

The jab will initially be offered to those unable to adhere to oral PrEP, such as individuals with gastrointestinal issues or those in unsafe living situations. According to the National Institute for Health and Care Excellence (NICE), patients will begin with two doses administered one month apart, followed by maintenance injections every two months. However, healthcare practitioners emphasize that this therapy should be accompanied by regular HIV screenings and safe sex practices.

In India, progress has been made in HIV prevention, but adherence to daily PrEP remains a challenge. Introducing a long-acting injectable like CAB-LA could greatly benefit vulnerable populations that face stigma or lack regular health care access. However, implementing this jab in India requires approval from the Drug Controller General of India (DCGI), cost assessments, and proper cold-chain storage facilities.

Additionally, awareness campaigns are essential to inform people about how the jab works and who it is intended for. Experts believe this is just the beginning of a new phase in HIV care. With other long-acting drugs, such as Lenacapavir, under global review, the future may lead to fewer doses, increased protection, and reduced stigma surrounding HIV prevention.

The landscape of HIV prevention is evolving from daily pills to bi-monthly shots, and potentially, to annual jabs in the future. The ultimate goal is to make prevention simpler, safer, and free of stigma.